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Background: Oxaliplatin, a platinum-based chemotherapeutic agent, causes an unusual acute peripheral
neuropathy. Oxaliplatin-induced acute peripheral neuropathy appears in almost all patients rapidly after infusion,
and is triggered or exacerbated by cold, while its mechanisms are poorly understood. In this study, the involvement
of thermosensitive transient receptor potential channels (TRPA1, TRPM8 and TRPV1) in oxaliplatin-induced acute
hypersensitivity was investigated in mice.
Results: A single intraperitoneal administration of oxaliplatin (1–10 mg/kg) induced cold but not mechanical
hypersensitivity within 2 h in a dose-dependent manner. Infusion of the oxaliplatin metabolite, oxalate
(1.7 mg/kg), also induced acute cold hypersensitivity, while another platinum-based chemotherapeutic agent,
cisplatin (5 mg/kg), or the non-platinum-containing chemotherapeutic agent, paclitaxel (6 mg/kg) failed to induce
mechanical or cold hypersensitivity. The oxaliplatin-induced acute cold hypersensitivity was abolished by the
TRPA1 antagonist HC-030031 (100 mg/kg) and by TRPA1 deficiency. The nocifensive behaviors evoked by
intraplantar injections of allyl-isothiocyanate (AITC; TRPA1 agonist) were significantly enhanced in mice treated for
2 h with oxaliplatin (1–10 mg/kg) in a dose-dependent manner, while capsaicin (TRPV1 agonist)-evoked nocifensive
behaviors were not affected. Menthol (TRPM8/TRPA1 agonist)-evoked nocifensive-like behaviors were also
enhanced by oxaliplatin pretreatment, which were inhibited by TRPA1 deficiency. Similarly, oxalate enhanced, but
neither cisplatin nor paclitaxel affected AITC-evoked nocifensive behaviors. Pretreatment of cultured mouse dorsal
root ganglia (DRG) neurons with oxaliplatin (30–300 μM) for 1, 2, or 4 h significantly increased the number of
AITC-sensitive neurons in a concentration-dependent manner whereas there was no change in the number of
menthol- or capsaicin-sensitive neurons.
Conclusions: Taken together, these results suggest that a brief treatment with oxaliplatin or its metabolite oxalate
is sufficient to enhance the responsiveness of TRPA1 but not that of TRPM8 and TRPV1 expressed by DRG neurons,
which may contribute to the characteristic acute peripheral neuropathy induced by oxaliplatin.
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Oxaliplatin, a third-generation, platinum-based chemo-
therapeutic agent, has superior activity as a first-line treat-
ment in advanced colorectal cancer [1] and as adjuvant
treatment [2]. Oxaliplatin has a better safety profile,
characterized by lower hematotoxicity and manageable
gastrointestinal toxicity, than other platinum-based* Correspondence: tnakaga@pharm.kyoto-u.ac.jp
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reproduction in any medium, provided the orchemotherapeutics. However, peripheral neuropathy is a
common side effect of platinum-based chemotherapeutic
compounds such as oxaliplatin and cisplatin, taxanes
such as paclitaxel and vinca alkaloids such as vincristine
[3]. Oxaliplatin induces moderate to severe peripheral
neuropathy, characterized by two types of neurological
symptoms [4,5]. During or within hours after its infu-
sion, an acute neuropathy, including acral numbness,
paresthesia, dysesthesia and pain, develops in almost all
patients that intensifies over time, causing serious dis-
comfort. The acute neuropathy is specific to oxaliplatintd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Zhao et al. Molecular Pain 2012, 8:55 Page 2 of 11
http://www.molecularpain.com/content/8/1/55and is triggered or exacerbated by cold [4-6]. After mul-
tiple chemotherapy cycles, chronic cumulative peripheral
neuropathy, such as sensory loss and motor dysfunction,
occurs in 10–15% of treated patients, a rate similar to
that of cisplatin [5,7]. While the oxaliplatin-induced
chronic peripheral neuropathy can be explained, at
least in part, by the accumulation of platinum adducts
in the dorsal root ganglia (DRG) [8], the mechanisms
underlying the acute peripheral neuropathy are poorly
understood.
Sensory neurons express several types of transient re-
ceptor potential (TRP) channels, including TRPV1, TRPA1,
and TRPM8. These receptors are thermosensitive and
play a critical role in pain generation [9,10]. TRPV1 is
activated by noxious heat, acidity, and noxious chemical
stimuli such as capsaicin [11,12]. TRPA1 is activated by
noxious cold and a large number of irritants including
allyl-isothiocyanate (AITC), cinnamaldehyde, allicin, and
aldehydes, as well as reactive-oxygen and nitrogen spe-
cies [13-16]. TRPM8 is activated by innocuous as well as
noxious cold, and by menthol, the ingredient of pepper-
mint that produces its cooling sensation [17,18]. Al-
though still a matter of debate, recent evidence suggests
that these thermosensitive TRP channels are responsi-
ble for chemotherapy-induced peripheral neuropathies.
In rodents, oxaliplatin increases the expression of TRPA1
[19-21] and TRPM8 [22], but see [19,21], but not TRPV1
[21], mRNAs in sensory ganglia. In mouse trigeminal
ganglia, cisplatin increases TRPV1 and TRPA1 mRNAs
levels [21], but see [23]. Oxaliplatin-induced mechanical
and cold hypersensitivity is abolished by pharmacolo-
gical inhibition or a gene-deficiency of TRPA1 [19,20],
TRPV1 [21], or TRPM8 [19,22], but see [23], and cisplatin-
and paclitaxel-induced painful neuropathy by an antag-
onist or genetic deficiency of TRPV1 [21,24,25]. In those
studies, chemotherapy-induced hypersensitivity was assessed
several days to several weeks after a single or repeated
administration of the compound, which may reflect the
subacute or chronic phase of chemotherapy-induced pe-
ripheral neuropathy.
In this study, we used a mouse model to investigate
whether TRPA1, TRPM8, and TRPV1 are involved in
the oxaliplatin-induced acute peripheral neuropathy. Here,
we show that, within hours, a single administration of
oxaliplatin, but not of cisplatin or paclitaxel, induces a
cold hypersensitivity that is associated with an enhanced
responsiveness of TRPA1, but not of TRPM8 and
TRPV1, on DRG neurons.
Results
Effect of oxaliplatin, cisplatin, and paclitaxel on acute
mechanical and cold sensitivities.
The effects of a single administration of oxaliplatin on
behavioral sensitivity to mechanical and cold stimuliwere assessed in a von Frey filament test and a cold-
plate test, respectively (Figure 1). A single intraperitoneal
administration of oxaliplatin (5 mg/kg) significantly de-
creased the 50% withdrawal threshold to mechanical
stimulation with von Frey filaments (F1,14 = 16.85, p< 0.01).
While a decrease in the mechanical threshold was not
apparent 2 h after oxaliplatin administration, the re-
sponse became significant at 1 day and lasted for at least
7 days, compared with the vehicle-administered group
(Figure 1A). In the cold-plate test, oxaliplatin (5 mg/kg)
significantly increased the escape behavior scores mea-
sured in response to cold stimulation (F1,10 = 10.06,
p< 0.01). Significant increases in the cold escape beha-
viors were observed after 2 h and lasted for at least
7 days after oxaliplatin administration, compared with
the vehicle-administered group (Figure 1B). We assessed
the dose-dependent effect of oxaliplatin on the acute
cold hypersensitivity in the cold-plate test. The cold es-
cape behavior scores were significantly increased 2 h
after the administration of oxaliplatin (1, 5 and 10 mg/kg)
in a dose-dependent manner (F3,20 = 18.57, p< 0.001),
and the significant effects were observed at doses of 5
and 10 mg/kg, but not 1 mg/kg, compared with the
vehicle-administered group (Figure 1C). Oxaliplatin is me-
tabolized to oxalate and dichloro(1,2-diaminocyclohexane)
platinum. As oxaliplatin-induced cold hypersensitivity
measured in the acetone test is caused, at least in part,
by oxalate [26], we examined the effect of oxalate on the
cold sensitivity in the cold-plate test. The dose of so-
dium oxalate (1.7 mg/kg) was calculated from the mo-
lecular weight of oxaliplatin included in the oxaliplatin
preparation (5 mg/kg). A single intraperitoneal adminis-
tration of oxalate significantly increased the cold escape
behavior scores (F1,12 = 14.81, p< 0.01). Significant in-
creases were observed after 2 h and lasted for 3 days
after oxaliplatin administration, compared with the vehicle-
administered group (Figure 1D).
The repeated administration of cisplatin or paclitaxel
is reported to produce mechanical and thermal hyper-
sensitivity, with maximal effects observed several days to
several weeks after drug administration [24,25,27,28]. In
this study, we asked whether cisplatin and paclitaxel in-
duce an early-phase acute mechanical or cold hyper-
sensitivity. However, 2 h after a single intraperitoneal
administration of cisplatin (5 mg/kg) or paclitaxel (6 mg/kg)
there was no change in the 50% withdrawal threshold
to mechanical stimulation) or in the escape behavior
scores measured in response to cold stimulation
(Figures 2).
Involvement of TRPA1 in acute oxaliplatin-induced
cold hypersensitivity.
To determine whether TRPA1 is involved in acute
oxaliplatin-induced cold hypersensitivity, we examined
the effects of a TRPA1 antagonist and of TRPA1
Figure 1 A single administration of oxaliplatin induces acute cold hypersensitivity, but not acute mechanical hypersensitivity. (A, B)
Mice were intraperitoneally administered either vehicle or oxaliplatin (5 mg/kg). At the indicated times, the 50% withdrawal threshold to
mechanical stimulation and escape behaviors in response to cold stimulation (5°C) were evaluated in a von Frey filament test (A, n=8) and a
cold-plate test (B, n= 6), respectively. Cold escape behaviors were scored depending on a behavioral assessment, with the total score calculated
for a period of 60 s. *p< 0.05, **p< 0.01, ***p< 0.001 compared with vehicle-administered group. (C) Mice were intraperitoneally administered
vehicle or oxaliplatin (1, 5 or 10 mg/kg). Two hours after the administration, the cold escape behaviors were scored in the cold-plate test.
n= 6. **p< 0.01; ***p< 0.001 compared with vehicle-administered group. (D) Mice were intraperitoneally administered either vehicle or
oxalate (1.7 mg/kg). At the indicated times, the cold escape behaviors were scored in the cold-plate test. n= 7. *p< 0.05 compared with
vehicle-administered group. Data are presented as the means ± S.E.M. Statistical significance was calculated by one-way ANOVA (C) or two-way
repeated measures ANOVA, followed by Bonferroni post-hoc test.
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measured in response to cold stimulation were signifi-
cantly higher in mice tested 2 h after oxaliplatin (5 mg/kg,
i.p.) administration than in mice tested 2 h after vehicle
administration. In 2 h vehicle-administered mice, an i.p.
injection of the TRPA1 antagonist HC-030031 (100 mg/kg)
30 min before the cold-plate test tended to decrease the
cold escape behavior scores, although the effect was not
significant. In 2-h oxaliplatin-administered mice, HC-
030031 significantly inhibited oxaliplatin-induced acute
cold hypersensitivity compared to 30-min vehicle-injected
mice (Figure 3A). Similarly, Trpa1+/+ mice exhibited acute
cold hypersensitivity 2 h after oxaliplatin (5 mg/kg) ad-
ministration, whereas the response was completely abol-
ished in Trpa1−/− mice (Figure 3B).
Effects of oxaliplatin, cisplatin, and paclitaxel on AITC-,
menthol- and capsaicin-evoked nocifensive behaviors.
To investigate the involvement of thermosensitive TRP
channels, we assessed the effects of oxaliplatin, cisplatin,
and paclitaxel on the nocifensive behaviors evoked by
TRP channel agonists. Intraplantar (i.pl.) injection of AITC(0.1%, 20 μl), a TRPA1 agonist, evoked nocifensive beha-
viors such as licking and flicking of the injected hind-
paw, whereas this was not the case following i.pl. vehicle
injection. When mice were preinjected with oxaliplatin
(1, 5 and 10 mg/kg, i.p.) and then tested 2 h later, the
duration of the AITC-evoked nocifensive behaviors were
significantly enhanced in a dose-dependent manner
(F3,31 = 5.711, p< 0.001). The significant differences were
observed at doses of 5 and 10 mg/kg, but not 1 mg/kg,
compared with mice preinjected with vehicle (Figure 4A).
We examined the time course of the oxaliplatin-induced
enhancement of the AITC-evoked nocifensive behaviors.
The duration of the AITC-evoked nocifensive behaviors
were significantly enhanced even 1 and 3 days, but not
7 days after a single administration of oxaliplatin (5 mg/kg,
i.p.), compared with mice preinjected with vehicle
(Figure 4B).
Intraplantar injection of menthol (160 μg), a TRPM8/
TRPA1 agonist [29], evoked nocifensive-like behaviors,
such as backwards walking and lifting of the injected
hindpaw. In mice preinjected with oxaliplatin 2 h prior
Figure 2 Neither cisplatin nor paclitaxel induces acute mechanical and cold hypersensitivity. Mice were intraperitoneally administered
vehicle, cisplatin (5 mg/kg; A, B), or paclitaxel (6 mg/kg; C, D), and 2 h later the 50% withdrawal threshold to mechanical stimulation (A, C) and
the escape behaviors in response to cold stimulation (B, D) were evaluated. Data are presented as the means ± S.E.M. of 6 mice.
Zhao et al. Molecular Pain 2012, 8:55 Page 4 of 11
http://www.molecularpain.com/content/8/1/55to testing, the scores of menthol-evoked nocifensive-like
behaviors were significantly higher than those of vehicle-
administered mice (Figure 4C). The enhancement of
menthol-evoked nocifensive-like behaviors induced by
oxaliplatin pretreatment was significantly inhibited in
Trpa1−/− mice to the scores in vehicle-pretreated mice
(Figure 4D). Intraplantar injection of the TRPV1 agonist
capsaicin (1.6 μg) evoked nocifensive behaviors such as
licking and flicking of the injected hindpaw. There was
no significant difference in the duration of the capsaicin-
evoked nocifensive behaviors between vehicle- and
oxaliplatin-preinjected mice (Figure 4E).
When mice were preinjected with oxalate (1.7 mg/kg,
i.p.) and then tested 2 h later, the duration of the AITC-
evoked nocifensive behaviors was significantly enhanced
compared with mice preinjected with vehicle (Figure 4F).
By contrast, a 2-h pre-injection of cisplatin (5 mg/kg, i.p.)
or paclitaxel (6 mg/kg, i.p.) had no effects on the duration
of the AITC-evoked nocifensive behaviors (Figures 4G, H).
Oxaliplatin enhances the response to TRPA1 agonist,
but not that of TRPM8 and TRPV1 agonists, in cultured
DRG neurons.
The effects of oxaliplatin pretreatment on the re-
sponses to TRPA1, TRPM8, and TRPV1 agonists in cul-
tured DRG neurons isolated from naïve mice were
assessed by calcium imaging. An application of the
TRPA1 agonist AITC at concentrations of 1, 10 and
100 μM to naïve cultured DRG neurons concentration-dependently evoked a [Ca2+]i increase in approximately
5.0 ± 1.3%, 22.2 ± 3.2% and 38.2 ± 2.8% of the cells, re-
spectively, consistent with previous reports (25–45%)
[29-31]. To better detect alterations of TRPA1 function,
cultured DRGs were treated with a relatively low AITC
concentration of 10 μM. In cultured DRG neurons pre-
treated with oxaliplatin (30, 100 and 300 μM) for 2 h,
the numbers of 10 μM AITC-sensitive cells were in-
creased in a concentration-dependent manner, although
the amplitudes of increase in F340/F380 ratio seemed to
be less or not increased (Figure 5). We quantitatively
assessed the numbers of AITC-sensitive cells. In cul-
tured DRG neurons pretreated with oxaliplatin (30 μM)
for 1, 2 and 4 h, the numbers of AITC-sensitive cells
were not changed, compared with those pretreated with
vehicle for 1, 2 and 4 h (F1,30 = 2.55, P=0.121) (Figure 6A).
By contrast, the numbers of AITC-sensitive cells pre-
treated with oxaliplatin (100 or 300 μM) for 1, 2 and 4 h
were significantly increased (F1,24 = 14,24, P< 0.001 and
F1,30 = 18.85, P< 0.001, respectively). Although the changes
became apparent at 1 h, significant differences reached
at 2 and 4 h of oxaliplatin pretreatment (Figure 6B, C).
An application of menthol (100 μM) evoked a [Ca2+]i
increase in 4–6% of cultured DRG neurons pretreated
with vehicle, which was consistent with (4.2-7% [32-34])
or less than previous reports (10-17% [17,23,30,35,36]).
In cultured DRG neurons pretreated with oxaliplatin
(100 μM) for 1, 2, or 4 h, there was no change in the
Figure 3 TRPA1 is involved in oxaliplatin-induced acute cold
hypersensitivity. (A) Mice were intraperitoneally administered
vehicle or oxaliplatin (5 mg/kg) 2 h before the cold-plate test, with
vehicle or HC-030031 (100 mg/kg) intraperitoneally injected 30 min
before testing. n= 6. (B) TRPA1+/+ or TRPA1−/− mice were
intraperitoneally administered vehicle or oxaliplatin (5 mg/kg) 2 h
before the cold-plate test. n= 7–8. Escape behaviors in response to
cold stimulation (5°C) were scored in a cold-plate test. Data are
presented as the mean± S.E.M. **p< 0.01, ***p< 0.001.
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(Figure 6D). Similarly, an application of capsaicin at a
relatively low concentration of 500 nM evoked a [Ca2+]i
increase in 22–29% of vehicle-treated cultured DRG
neurons, with no change in the number of capsaicin-
sensitive cells at any time point in those pretreated with
oxaliplatin (Figure 6E).
Discussion
In the present study, we provide the first evidence that
TRPA1 in DRG neurons mediates the acute phase of
oxaliplatin-induced peripheral neuropathy, as supportedby the following results. 1) A single administration of
oxaliplatin, as well as its metabolite oxalate, produced
rapid-onset cold hypersensitivity within 2 h; this re-
sponse was blocked by a TRPA1 antagonist and by
TRPA1 deficiency. 2) Nocifensive behaviors evoked by
AITC and menthol, but not by capsaicin, were enhanced
2 h after oxaliplatin administration. 3) Pretreatment of
the cultured DRG neurons with oxaliplatin for 2–4 h
increased the number of AITC-, but not of menthol-
and capsaicin-sensitive neurons.
The peripheral neuropathy caused by chemotherapeu-
tic agents, including oxaliplatin, has been widely evalu-
ated experimentally in rodents as hypersensitivity to
mechanical and thermal stimuli in terms of mechanical
allodynia and thermal hyperalgesia, respectively. Pre-
vious studies in animal models largely focus on the
oxaliplatin-induced chronic painful neuropathy that ap-
pears several days to several weeks after oxaliplatin ad-
ministration [19-22,37], while oxaliplatin-induced acute
neuropathy is less well characterized [26]. Our findings
in mice, in which cold hypersensitivity was detected as
early as 2 h after oxaliplatin administration, is consistent
with the clinical observation of a characteristic acute
sensory neuropathy triggered by cold that appears dur-
ing or within hours of oxaliplatin infusion. By contrast,
mechanical hypersensitivity in mice was observed 1 day,
but not as early as 2 h, after drug administration and
persisted for at least 7 days, consistent with previous
reports [20,26,37]. Moreover, the rapid-onset cold hyper-
sensitivity was not produced by another platinum-based
chemotherapeutic agent, cisplatin, or by the non-platinum-
containing chemotherapeutic agent, paclitaxel, both of
which are known to induce chronic peripheral neuro-
pathy following repeated administration [24,25,27,28].
These findings suggest that the rapid-onset cold hyper-
sensitivity is representative of the acute peripheral sen-
sory neuropathy characteristic to oxaliplatin in mice and
that the mouse model is suitable for evaluating the
mechanisms of this side effect.
The major finding of this study is that oxaliplatin leads
to the selective enhancement of TRPA1-mediated re-
sponses within a relatively short time, both in vivo and
in vitro. AITC-evoked nocifensive behaviors and Ca2+
influx in DRG neurons are mediated through the activa-
tion of TRPA1 [29,38]. Oxaliplatin increased both of these
TRPA1-mediated responses within several hours, sug-
gesting that it rapidly leads to an enhanced TRPA1 re-
sponsiveness in sensory neurons. The finding that oxalate
enhanced AITC-evoked nocifensive behaviors suggests
that the rapid-onset effects characteristic of oxaliplatin
are caused by its metabolite, oxalate, or by an oxalate-
related structure of oxaliplatin. Consistent with our find-
ings, Sakurai et al. showed that both oxaliplatin and oxalate
induce an early-phase (several hours) cold hyperalgesia
Figure 4 A single administration of oxaliplatin, but not cisplatin and paclitaxel, enhances AITC-evoked nocifensive behaviors. (A) Two
hours after a single administration of vehicle or oxaliplatin (1, 5 or 10 mg/kg), mice received an intraplantar injection of vehicle (n= 3) or AITC
(0.1%, 20 μl; n= 7–14). (B) 1, 3 or 7 days after a single administration of vehicle or oxaliplatin (5 mg/kg), mice received an intraplantar injection of
AITC (0.1%, 20 μl). n= 5–6. (C) Two hours after a single administration of vehicle or oxaliplatin (5 mg/kg), mice received an intraplantar injection of
vehicle or menthol (1.6 μg, 20 μl). n= 6. (D) TRPA1+/+ or TRPA1−/− mice were intraperitoneally administered vehicle or oxaliplatin (5 mg/kg) 2 h
before the menthol-evoked nocifensive behaviors. n= 3–4. (E) Two hours after a single administration of vehicle or oxaliplatin (5 mg/kg), mice
received an intraplantar injection of vehicle or capsaicin (160 μg, 20 μl). n= 6. (F–G) Two hours after a single administration of oxalate (1.7 mg/kg;
F), cisplatin (5 mg/kg; G), paclitaxel (6 mg/kg; H) or vehicle, mice received an intraplantar injection of AITC (0.1%, 20 μl). n= 6–7. AITC- and
capsaicin-evoked nocifensive behaviors were measured for 20 min and 5 min, respectively; menthol-evoked nocifensive-like behaviors were
scored for 5 min. Data are presented as the means ± S.E.M. *p< 0.05; **p< 0.01; ***p< 0.001.
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allodynia is induced by oxaliplatin or its another metab-
olite dichloro(1,2-diaminocyclohexane)platinum, but not
oxalate, in rats [26]. On the other hand, the oxaliplatin-
induced enhancement of AITC-evoked nocifensive be-
haviors lasted, at least, 3 days after the administration,
suggesting that the enhanced TRPA1 responsiveness con-
tributes to not only the acute (several hours), but also, at
least, subacute (several days) oxaliplatin-induced cold
hypersensitivity.
Despite some controversies, recent evidence points to
the involvement of TRPA1 in oxaliplatin-induced sub-
acute and chronic peripheral neuropathy [19-21,39]. Sub-
acute (several days) mechanical and cold hypersensitivitiesinduced by a single administration of oxaliplatin were
shown to be inhibited by either a TRPA1 antagonist or
TRPA1 deficiency [19,20], while the antagonist failed to
inhibit the oxaliplatin-enhanced cold-temperature avoid-
ance behavior [19]. Furthermore, subacute (several days)
and chronic (several weeks) administration of oxaliplatin
increases TRPA1 mRNA levels in DRGs and in the tri-
geminal ganglion [19,21]. Controversially, a transient up-
regulation of TRPA1 mRNA is observed in DRGs only
6 h after a single administration of oxaliplatin [20].
However, it is unlikely that oxaliplatin is able to increase
the expression of functional TRPA1 protein within several
hours of its administration. In the Ca2+ imaging experi-
ments of the present study, the AITC concentration was
Figure 5 Oxaliplatin pretreatment increases the AITC-evoked Ca2+ response in cultured DRG neurons. The cultured neurons were
pretreated with vehicle (A) or oxaliplatin at concentrations of 30 (B), 100 (C) or 300 μM (D) for 2 h after which AITC (10 μM) was added for 3 min.
Representative image of fluorescence (upper panels) and Ca2+ concentration (F340/F380 ratio) recorded in individual cultured DRG neuron (lower
panels). All neurons in the fields were identified based on the [Ca2+]i increase elicited by the application of 50 mM KCl. Cell numbers in (AITC-
sensitive DRG neurons)/(Total counted neurons) in the representative data are indicated in parentheses in lower panels.
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platin treatment, 10 μM AITC produced nearly the same
proportion of sensitive neurons (approximately 40%) as
obtained with the submaximal concentration of AITC
(100 μM) used in the control. Therefore, it is likely that
oxaliplatin acutely produces an enhanced TRPA1 re-
sponsiveness by increasing the sensitivity to AITC, i.e.,
through the sensitization of existing TRPA1 and not by
an increase in the number of TRPA1-expressing cells.
Under inflammatory conditions, TRPA1 sensitization in-
volves its translocation to the plasma membrane via
phospholipase C and protein kinase A (PKA) signaling
[40,41]. Acute oxaliplatin may likewise induce the TRPA1
sensitization via PKA signaling [39] or through other
mechanisms specific to oxaliplatin and oxalate.
TRPM8 is expressed in a subpopulation of small-
diameter sensory neurons, which correlates with re-
sponses to cooling and menthol [18,42,43]. Menthol
sensation is mainly ascribed to TRPM8, while it also
activates TRPA1 in a bimodal manner [29]. In Ca2+ im-
aging experiments, menthol-sensitive DRG neurons are
largely abolished in TRPM8−/− mice, although a small
population of menthol-sensitive neurons remains, prob-
ably via TRPA1 activation [32,44]. Nevertheless, we found
no change in the number of menthol-sensitive DRG
neurons in response to oxaliplatin, suggesting that it has
no acute effect on TRPM8-mediated responses. Although
menthol-sensitive DRG neurons mediated thorough TRPA1
activation might be increased by acute oxaliplatin, they
may be undetectable probably due to too small populationor weak activation of TRPA1 by 100 μM menthol in a
bimodal phase [29]. Supporting our findings, oxaliplatin
enhances Ca2+ responses to icilin (TRPA1/TRPM8
agonist), but not WS12 (TRPM8 selective agonist), in rat
DRG neurons [39]. By contrast, our present findings
showed that menthol-evoked nocifensive-like behaviors
were enhanced after acute oxaliplatin administration,
which was inhibited by TRPA1 deficiency. Since it is
possible that menthol-evoked nocifensive-like behaviors
are mediated through TRPA1 activation [45], they may
be increased by the enhanced responsiveness of TRPA1
after acute oxaliplatin administration in the dose of
menthol used in this study. Several studies examine the
involvement of TRPM8 in oxaliplatin-induced peripheral
neuropathy. The subacute, but not chronic, effects of
oxaliplatin administration were shown to include a tran-
sient up-regulation of TRPM8 mRNA in DRGs [19,21,22].
In TRPM8−/− mice, oxaliplatin-enhanced cold avoidance
is abolished, while there is no change in oxaliplatin-
induced mechanical hypersensitivity [19]. Pharmacological
blockade of TRPM8 has no effect on oxaliplatin-induced
subacute cold hypersensitivity [23]. Thus, although TRPM8
involvement in oxaliplatin-induced subacute peripheral
neuropathy remains to be clarified, our findings seem to
rule out an important role for TRPM8 in oxaliplatin-
induced acute peripheral neuropathy.
A body of evidence suggests that TRPV1 plays a role
in chemotherapy-induced chronic peripheral neuropathy
[21,24,25], similar to the neuropathic pain induced by
peripheral nerve injury [46]. However, in the present study,
Figure 6 Oxaliplatin pretreatment increases the number of AITC-sensitive DRG neurons. (A-C) In cultured DRG neurons pretreated with
vehicle or oxaliplatin at concentrations of 30 (A), 100 (B) or 300 μM (C) for 1, 2, or 4 h, AITC (10 μM) was added for 3 min. (D, E) In cultured DRG
neurons pretreated with vehicle or oxaliplatin (100 μM) for 1, 2, or 4 h, menthol (100 μM; D) or capsaicin (500 nM; E) was added for 3 min, and
the Ca2+ responses of the neurons were determined. Cells were considered responsive if their F340/F380 ratio increased by more than 0.2 during
the 3-min application. The values show the percentage of agonist-sensitive cells in 50 mM KCl-positive neurons. Data are presented as the
mean± S.E.M. of 4–6 separate experiments. *p< 0.05, compared with corresponding vehicle-pretreatment.
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TRPV1-mediated nocifensive behaviors. Furthermore, oxa-
liplatin had no rapid-onset effect on capsaicin-evoked noci-
fensive behaviors or the number of capsaicin-sensitive
DRG neurons, suggesting that oxaliplatin-induced acute
peripheral neuropathy is not mediated by TRPV1. Consist-
ent with the present findings, other studies did not find
evidence of TRPV1 involvement in oxaliplatin-induced
subacute and chronic cold hypersensitivity [20-22].Accumulating evidence suggests that oxaliplatin, as a
platinum-based drug like cisplatin, induces chronic per-
ipheral neuropathy by its direct and indirect neurotoxic
effects on peripheral sensory neurons [5,20]. The painful
neurotoxicity may secondarily up-regulate and/or sensi-
tize TRPA1, TRPV1, and TRPM8, as occurs in nerve
injury-induced neuropathic pain [46-48]. However, our
results indicate that oxaliplatin leads to a rapid, prefer-
entially enhanced responsiveness of TRPA1. Since the
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toxicity on sensory neurons, a more likely explanation is
an alteration in TRPA1 function, either directly or indi-
rectly, within several hours, although the mechanisms
remain unclear.
Conclusions
The present data suggest that the acute cold hypersensi-
tivity characteristically induced by oxaliplatin could be
linked to an enhanced responsiveness of TRPA1, but not
TRPM8 and TRPV1, on DRG neurons. This pathway
may also be involved in other acute symptoms produced
in response to oxaliplatin, such as acral numbness,
paresthesia, and dysesthesia. Confirmation of these find-
ings would allow the molecular targeting of TRPA1 in




The male C57BL/6 J mice aged between 6–8 weeks-old
were purchased from Japan SLC (Shizuoka, Japan). For
experiments investigating the effects of TRPA1 defi-
ciency, wild-type (Trpa1+/+) and homozygous (Trpa1−/−)
mouse littermates from heterozygous/heterozygous Trpa1+/−
mice were used (6- to 8-weeks-old). Trpa1−/− mice bred
from heterozygous mice with a C57BL/6 × 129 S1 back-
ground were obtained from Jackson Laboratory (Bar
Harbor, ME) and genotyped as previously described [38].
The Trpa1−/− mouse line was backcrossed to C57BL/6 J
mice for at least 10 generations. All mice were housed
under constant ambient temperature (24 ± 1°C) and hu-
midity (55 ± 10%), with alternate light–dark cycles from
8:00 a.m. to 20:00 p.m.. Food and water were freely avail-
able. All experiments were conducted in accordance
with the Ethical Guidelines of the Kyoto University Ani-
mal Experimentation Committee.
Drugs
Oxaliplatin and sodium oxalate were purchased from Wako
Pure Chemical Industries, Ltd. (Osaka, Japan) and freshly
dissolved in 5% glucose solution. cis-Diammineplatinum(II)
dichloride (cisplatin) and paclitaxel were purchased
from Sigma-Aldrich, Inc. (St. Louis, MO, USA). Cisplatin
was freshly dissolved in sterile saline, and paclitaxel in
CremophorW EL (Sigma-Aldrich) and dehydrated ethanol
(1:1) to obtain a stock solution. Prior to its administra-
tion, paclitaxel was further diluted with sterile saline.
Mice received a single intraperitoneal administration of
oxaliplatin (1, 5 or 10 mg/kg), cisplatin (5 mg/kg), paclitaxel
(6 mg/kg), or vehicle. The doses of these chemothera-
peutic agents were chosen based on previous reports with
a single intraperitoneal administration [19,26,28,37,49,50].HC-030031 (100 mg/kg, Enzo Life Sciences, Exeter, UK)
was prepared in 0.5% methylcellulose (Wako).
Behavioral tests
von Frey filament test
Mechanical sensitivity was assessed by the up-down meth-
od using calibrated von Frey filaments, as previously de-
scribed with slight modifications [51,52]. Mice were
acclimated on a wire-mesh floor in Plexiglas cubicles
(9 cm L× 5 cm W×5 cm H) for 1 h, after which mech-
anical sensitivity was evaluated using a set of four cali-
brated von Frey fibers (0.07, 0.16, 0.4, 1.0 g; Stoelting
Co., Wood Dale, IL USA) applied to the plantar surface
of the left hindpaw for a few seconds until they bent
slightly. A withdrawal reflex of the hindpaw during stim-
ulation or immediately after stimulus removal was con-
sidered a positive response. If a positive response was
obtained to the first stimulus, the 0.16-g filament, then
the next lower filament was applied; if there was no re-
sponse, the next higher filament was used. After the first
change in responses, the experiment was continued until
four additional responses were obtained. The 50% paw
withdrawal threshold value was then calculated (Chaplan
et al., 1994).
Cold-plate test
Cold sensitivity was assessed with the hot/cold-plate
analgesimeter (Ugo Basile, Milan, Italy). Mice were al-
lowed to acclimate to the testing apparatus for 1 h, after
which they were individually placed on the center of a
cold plate maintained at 5°C in a transparent Plexiglas
cylinder. Escape behaviors were observed for 60 s and
graded with a score of 0 = no response; 1 =moderate ef-
fort to avoid cold, such as lifting a hindpaw or walking
backwards; and 2 = vigorous effort to escape cold, such
as jumping. The sum of the scores recorded within a 60-s
period was calculated.
TRP channel agonist-evoked nocifensive behaviors
DL-Menthol (Sigma-Aldrich) and capsaicin (Nacalai Tesque,
Kyoto, Japan) were dissolved in dimethyl sulfoxide (DMSO)
as a stock solution (800 mg/ml and 80 mg/ml, respect-
ively). Allyl-isothiocyanate (AITC, Wako), menthol, and
capsaicin were diluted in corn oil (Sigma-Aldrich). The
mice were allowed to acclimate in a clear acrylic cylinder
for at least 40 min after which 20 μl of AITC (0.1%),
capsaicin (1.6 μg) or menthol (160 μg) was subcutane-
ously injected into the plantar surface of the left hind-
paw. AITC- and capsaicin-evoked nocifensive behaviors
were measured as the durations of consecutive licking
and flicking behaviors for 20 min and 5 min, respect-
ively. Menthol-evoked nocifensive-like behaviors (i.e.,
hindpaw lifting and backwards walking) were scored as
for the cold-plate test described above. The sum of the
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calculated.Primary cultures of DRG neurons
Bilateral L1-L6 DRGs were harvested from two freshly
killed adult male C57BL/6 J mice. DRGs were incubated
for 1 h at 37°C in Hank's balanced salt solution
(137 mM NaCl, 5.4 mM KCl, 0.34 mM Na2HPO4,
0.44 mM KH2PO4, 5.6 mM D-glucose, 2.4 mM HEPES,
25 mM glucose, pH 7.4) containing 0.3% collagenase
and 0.4% dispase. A Percoll (Sigma-Aldrich) gradient
was used to separate myelin and nerve debris from DRG
neurons as follows: Solutions of 30% and 60% Percoll
were prepared with L15 medium. The 30% Percoll was
gently layered over the 60% Percoll solution, and the cell
suspension over the Percoll gradient. After 10 min of
centrifugation at 1800 × g, the cells were harvested from
the Percoll interface and suspended in 8 ml L15
medium, then centrifuged again for 5 min at 1800 × g.
The supernatant was removed and the cell pellet resus-
pended in 70 μl Dulbecco's modified Eagle medium
(DMEM), containing 10% heat-inactivated fetal bovine
serum, penicillin G (100 U/ml), and streptomycin (100 μg/ml),
followed by plating onto laminin-coated coverslips
(3 mm×7 mm) and incubation at 37°C. After 4 h incu-
bation, 1.5 ml DMEM was added and the cells were
incubated again, this time overnight at 37°C.Fluorometric Ca2+ imaging
Cultured DRG neurons on coverslips were loaded for
30 min with 5 μM fura-2/AM (Dojindo, Kumamoto,
Japan) in Krebs-Ringer solution (140 mM NaCl, 5 mM
KCl, 1 mM MgCl2, 2 mM CaCl2, 10 mM glucose, 10 mM
HEPES) containing 0.01% cremophore EL (Sigma-Aldrich).
The cells were then washed with Krebs-Ringer solu-
tion and transferred to an imaging chamber. The
AQUACOSMOS/ORCA-AG imaging system (Hamamatsu
Photonics, Shizuoka, Japan) was used to capture the
fluorescence images obtained with alternating excitation
at 340 and 380 nm and emission at> 510 nm. Emission
ratios (F340/F380) were calculated for each 5-s interval
after subtraction of the background. The cells showing
the F340/F380 ratio of over 1.4 at the baseline were ex-
cluded. A cellular response to a drug was defined as an
increase in the F340/F380 ratio by more than 0.2 during
the 3-min application period. All experiments were per-
formed at room temperature. Oxaliplatin stock solution
(5 mM) was prepared in sterile water and further diluted
in DMEM to 100 μM before every experiment. AITC
(100 mM), menthol (1 M), and capsaicin (100 mM) were
prepared as stock solutions in DMSO and diluted in
Krebs-Ringer solution.Statistical analysis
The data were analyzed using Graphpad Prism and are
presented as means ± S.E.M. Statistical significance was
calculated by one-way or two-way analyses of variance
(ANOVA), followed by the Bonferroni post-hoc test.
Time-course data were analyzed by two-way ANOVA
for repeated measures, followed by the Bonferroni post-
hoc test. In all cases, differences of p< 0.05 were consid-
ered statistically significant.
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